Get started
Author

Yunwei Han

Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
2024 · Zefei Jiang, Quchang Ouyang, et al. · Nature Medicine · 131
Paclitaxel-loaded polymeric nanoparticles combined with chronomodulated chemotherapy on lung cancer: In vitro and in vivo evaluation
2016 · Jie Hu, Shaozhi Fu, et al. · International Journal of Pharmaceutics · 84
External radiotherapy combined with sorafenib has better efficacy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis
2022 · Han Li, Zhenying Wu, et al. · Clinical and Experimental Medicine · 42
PDF
Enhanced antitumor and anti-angiogenic effects of metronomic Vinorelbine combined with Endostar on Lewis lung carcinoma
2018 · Rong-Sheng Qin, Zhen-Hua Zhang, et al. · BMC Cancer · 30
PDF
Discovery of a novel megakaryopoiesis enhancer, ingenol, promoting thrombopoiesis through PI3K-Akt signaling independent of thrombopoietin
2022 · Long Wang, Ting Zhang, et al. · Pharmacological Research · 29
Radiomics for Diagnosis and Radiotherapy of Nasopharyngeal Carcinoma
2022 · Yu-mei Zhang, Guan-zhong Gong, et al. · Frontiers in Oncology · 28
PDF
Biological Role and Mechanism of Lipid Metabolism Reprogramming Related Gene ECHS1 in Cancer
2022 · Teng Hu, Xiaojing Chen, et al. · Technology in Cancer Research & Treatment · 23
Platelet transfusion for cancer secondary thrombocytopenia: Platelet and cancer cell interaction
2021 · Juan Wang, Pan Zhou, et al. · Translational Oncology · 22
PDF
Clinical efficacy and safety of external radiotherapy combined with sorafenib in the treatment of hepatocellular carcinoma: a systematic review and meta-analysis
2022 · Jiali Chen, Kun He, et al. · Annals of Hepatology · 16
PDF
Novel chemical-structure TPOR agonist, TMEA, promotes megakaryocytes differentiation and thrombopoiesis via mTOR and ERK signalings
2022 · Xueqin Jiang, Yueshan Sun, et al. · Phytomedicine · 13
Effectiveness of c-TACE Combined With Sorafenib Versus c-TACE Monotherapy in Advanced Hepatocellular Carcinoma: A Retrospective Study
2023 · Shanshan Liu, Yunwei Han, et al. · Clinical Medicine Insights Oncology · 10
Nemo-like kinase expression predicts poor survival in colorectal cancer
2014 · JINGBO CHEN, YUNWEI HAN, et al. · Molecular Medicine Reports · 7
PDF
Loss of Heterozygosity of 9p Is Associated with Poorer Survival in Patients with Gliomas
2015 · Tingfen Huang, Shufa Li, et al. · Molecular Neurobiology · 6
Comparison of the efficacy and safety of selective internal radiotherapy and sorafenib alone or combined for hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis
2023 · Hao Zeng, Chengyuan Zhou, et al. · Clinical and Experimental Medicine · 5
PDF
A propensity score matching study on survival benefits of radiotherapy in patients with inoperable hepatocellular carcinoma
2023 · Hao Zeng, Ke Su, et al. · Scientific Reports · 4
PDF
Efficacy of granulocyte-macrophage colony-stimulating factor combined with metronomic paclitaxel in the treatment of Lewis lung carcinoma transplanted in mice
2017 · Nengping Zhu, Rongsheng Qin, et al. · Oncotarget · 3
PDF
Nomogram model based on γ-glutamyl transferase to albumin ratio predicts survival in hepatocellular carcinoma patients with transarterial chemoembolization treatment
2024 · Zhen-Ying Wu, Han Li, et al. · World Journal of Gastrointestinal Oncology · 2
PDF
Construction and validation of a nomogram for overall survival prognosis in patients with advanced (stage III/IV) pancreatic cancer
2026 · Dongqi Yang, Chenjie Wang, et al. · Scientific Reports · 1
PDF
Corrigendum to “Paclitaxel-loaded polymeric nanoparticles combined with chronomodulated chemotherapy on lung cancer: In vitro and in vivo evaluation” [Int. J. Pharmaceut. 516 (2017) 313–322]
2019 · Jie Hu, Shaozhi Fu, et al. · International Journal of Pharmaceutics · 1
Multi‐Omics‐Enabled Precision Strategies for Overcoming CAR ‐T Therapy Limitations in Gastrointestinal Malignancies
2026 · Ke Su, Zunyuan Tan, et al. · BioFactors
PDF
Survival benefit of radiotherapy in patients with inoperable hepatocellular carcinoma: a propensity score matching study
2022 · Hao Zeng, Ke Su, et al. · Research Square
PDF
Update of a phase II, multicenter clinical trial: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC.
2022 · Jin Yan, Yunwei Han, et al. · Journal of Clinical Oncology
Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC: A single-arm, multicenter, phase II clinical trial—Update results from ALTER-C001.
2022 · Jin Yan, Yunwei Han, et al. · Journal of Clinical Oncology
Update results from ALTER-C-001: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC-A single-arm, multicenter, phase Ⅱ clinical trial.
2021 · Jin Yan, Yunwei Han, et al. · Journal of Clinical Oncology
ALTER-C-001: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC—A single-arm, multicenter, phase Ⅱ clinical trial.
2021 · Jin Yan, Li Zhang, et al. · Journal of Clinical Oncology
Works count: 26
Citation count: 457
H-index: 10
I10-index: 11
Year
Topic
Type